Innovation of a method to maintain focus of an Oesophageal Doppler probe - continuation of Project 104939

德尔特斯很高兴地宣布，它通过成功竞标第四轮创新者分析：迷你项目第二阶段竞赛，获得了Innovate UK的资金。这项创新英国基金带来了与世界级英国机构合作的机会，以寻求改善现有技术的解决方案。Deltex Medical很高兴与美国国家物理实验室(NPL)合作，加强其血流动力学监测探头的设计。Deltex是血流动力学监测的多普勒超声领域的世界领先者。使用该公司的TrueVue多普勒，已被证明可以减少术后并发症，NICE推荐使用。该系统还为医院节省了治疗并发症的成本，否则将导致住院时间延长。微创TrueVue多普勒技术使用插入患者食道(食物管道)的超声波探头。食道靠近病人胸部的大动脉，因此可以测量血流速度，就像警察的测速摄像头检查汽车的速度一样。在这种情况下，移动的物体是血细胞。TrueVue系统测量血流速度和每次心跳的时间。TrueVue然后计算出一系列参数，对临床医生在管理病人护理方面有用，以最大限度地减少甚至预防术后并发症。临床医生利用他们的心血管解剖知识和他们在TrueVue监护仪上看到的超声信号，通过感觉和导航来实现探头的聚焦。他们旋转和操纵探头的深度，以找到最佳的主动脉血流信号。Deltex将使用赠款资金与NPL合作进行一项研究，开发超声波透镜，以优化产品的波束宽度和功率输出。更宽的射束有两个优点；第一，发现主动脉血流更快；第二，患者或设备的任何移动都不会使射束偏离焦点。结果将是，用户将对该设备更有信心，从而增加对NICE公司证实的一项技术的使用，该技术可以减少术后并发症、住院时间(-3天)和医疗成本(每个患者1,100 GB)。该项目将通过改进易用性而使临床医生和患者受益。Deltex预计，这一结果将扩大已经被证明有效的医疗设备的使用范围。“

"Deltex is pleased to announce that it has gained Innovate UK funding through a successful bid to the Analysis for innovators round 4: mini projects phase 2 competition. This Innovate UK funding brings with it the opportunity to collaborate with world-class UK agencies to seek solutions to improve existing technologies. Deltex Medical is pleased to be partnering with the National Physics Laboratory (NPL) in a project to enhance the design of its haemodynamic monitoring probes.Deltex is the world leader in Doppler ultrasound for haemodynamic monitoring. Use of the company's TrueVue Doppler, is proven to reduce post-operative complications and is recommended by NICE. The system also saves hospitals the costs of treating complications that would otherwise result in increased lengths of stay.The minimally invasive TrueVue Doppler technology uses an ultrasound probe inserted into the patient's oesophagus (food pipe). The oesophagus lies close to the aorta in the patient's chest and so blood flow velocity can be measured much like a police speed camera checks a car's speed. In this case the moving objects are blood cells.The TrueVue system measures blood flow velocity and the timing of each heartbeat. TrueVue then calculates a range of parameters useful to clinicians in managing patient care to minimise or even prevent post-operative complications. Clinician's achieve focus of the probe by feel, navigating using their knowledge of cardiovascular anatomy and the ultrasound signal they view on the TrueVue monitor. They rotate and manipulate the depth of the probe to find the optimum aortic blood flow signal.Deltex will use the grant monies to collaborate with NPL in a study to develop ultrasound lenses to optimise the product's beam width and power output. The advantages of a wider beam are two-fold; firstly finding the aortic blood flow is quicker; and secondly any movement of the patient or equipment has less potential to move the beam out of focus. The result will be that users will be more confident with the device leading to increased use of a technology proven by NICE to reduce post-operative complications, hospital stay (-3 days) and healthcare costs (£1,100 per patient).The project will benefit clinicians and patients by leading to ease of use improvements. Deltex expects that the outcome will increase the range of uses of a medical device with already proven efficacy."